Source:http://linkedlifedata.com/resource/pubmed/id/16365914
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2006-2-7
|
pubmed:abstractText |
Lipopolysaccharide (LPS) endotoxin is the bacterial product responsible for the clinical syndrome of Gram-negative septicemia and endotoxic shock. During sepsis, microbial antigens, such as LPS, activate monocytes and macrophages to produce several pro-inflammatory cytokines, among which tumor necrosis factor-alpha (TNF-alpha) appears to be very important for the development of endotoxic shock. The endotoxic properties of LPS principally reside in the lipid A (LIP A) component, which is the primary immunostimulatory center of Gram-negative bacteria. In recent years there has been a continuous effort to identify molecules able to antagonize the deleterious effects of endotoxic shock. In this study we show that a novel LIP A fraction from the LPS of Halomonas magadiensis (Hm), a Gram-negative extremophilic and alkaliphilic bacterium, significantly inhibits the synthesis of TNF-alpha by human monocytes activated by Escherichia coli LPS. LIP A from Hm exerts these effects by interfering with E. coli LPS for activation of Toll-like receptor 4 expressed in human cells. This result defines Hm LIP A as a novel class of LPS antagonist whose structural features could be utilized for the design of compounds for the treatment of Gram-negative sepsis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0014-2980
|
pubmed:author |
pubmed-author:Di MeglioPaolaP,
pubmed-author:Di RosaMassimoM,
pubmed-author:GrantWilliamW,
pubmed-author:GrassiaGianlucaG,
pubmed-author:IalentiArmandoA,
pubmed-author:IanaroAngelaA,
pubmed-author:LanzettaRosaR,
pubmed-author:MaffiaPasqualeP,
pubmed-author:MolinaroAntonioA,
pubmed-author:SilipoAlbaA
|
pubmed:issnType |
Print
|
pubmed:volume |
36
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
354-60
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16365914-Cell Line,
pubmed-meshheading:16365914-Drug Antagonism,
pubmed-meshheading:16365914-Escherichia coli,
pubmed-meshheading:16365914-Halomonas,
pubmed-meshheading:16365914-Humans,
pubmed-meshheading:16365914-Lipid A,
pubmed-meshheading:16365914-Macrophage Activation,
pubmed-meshheading:16365914-Monocytes,
pubmed-meshheading:16365914-Shock, Septic,
pubmed-meshheading:16365914-Species Specificity,
pubmed-meshheading:16365914-Toll-Like Receptor 4,
pubmed-meshheading:16365914-Tumor Necrosis Factor-alpha
|
pubmed:year |
2006
|
pubmed:articleTitle |
A novel lipid A from Halomonas magadiensis inhibits enteric LPS-induced human monocyte activation.
|
pubmed:affiliation |
Department of Experimental Pharmacology, University of Naples Federico II, 80131 Naples, Italy.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|